Compare Twist Bioscience Corp (TWST) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Wells Fargo & Co — how do they compare? Twist Bioscience Corp trades at $88.31 (market cap $5.45B), while Wells Fargo & Co trades at $88.03 (market cap $261.45B). The key difference: Wells Fargo & Co is far larger — about 48× Twist Bioscience Corp's market cap, and Wells Fargo & Co pays a 2.09% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | WFC | |
|---|---|---|
Market Cap | $5.45B | $261.45B |
Sector | Health | Financials |
52-Week High | $102.88 | $96.40 |
52-Week Low | $24.16 | $73.42 |
Enterprise Value | $5.37B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Wells Fargo (WFC) trades at $87.75, up 0.26% today, with a neutral technical signal and bullish moving averages. The stock shows improving fundamentals with 2025 revenue of $83.70B and net income of $21.34B, yielding a 25.97% net margin. Recent Q2 2026 earnings beat expectations with EPS of $1.96 versus $1.73 expected. Analyst consensus is mixed with a $97.36 price target, suggesting 11% upside. The bank continues growth initiatives post-asset cap removal, though net cash flow remains negative.
Outlook remains cautiously optimistic given valuation support (P/E 12.55) and dividend yield, but risks include net interest margin pressure and volatile cash flows. Institutional activity is mixed with some trimming positions. Earnings sustainability and loan growth execution are key catalysts for further upside, while macroeconomic sensitivity poses a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
